Rationale
Sustained exposure can unlock the potential of proven pharmacology.
Many therapeutically compelling molecules are limited by pharmacokinetic properties that constrain efficacy. Piston Bio is developing extended half-life medicine designed to provide sustained therapeutic exposure while building on established pharmacology and clinical experience.

Our Approach

From validated biology to meaningful impact.
Piston Bio develops extended half-life versions of clinically characterized medicine through a focused, capital-efficient development strategy designed to create differentiated therapies for patients with cancer.


Piston Bio
New medicine for cancer.
Small molecules and biologics for the mind and body.
Small molecules have a big repertoire.

Mind and body are inseparable.

Biologics are on deck.

100% owned
Pipeline
PST-102
non-binding licensing terms agreed with Roche
mosperafenib
BRAF V600E inhibitor - oncology
A2A antagonist - oncology/CNS
PST-101
TLR7/8 agonist - oncology
100% owned




